INCY · 10-Q · 2026Q3 · Full report

NIKTIMVO Product Positioning

INCYTE CORP · 2026-10-29 · Importance 12 · Surprise 6

NIKTIMVO (axatilimab-csfr) was approved in the United States in August 2024 for chronic graft-versus-host disease after failure of at least two prior systemic therapy lines in adults and pediatric patients. Incyte describes it as the first approved anti-CSF-1R antibody targeting drivers of inflammation and fibrosis in chronic GVHD. Its U.S. commercial launch began in January 2025.

Key facts

• The U.S. commercial launch of NIKTIMVO commenced in January 2025; it is the first approved anti-CSF-1R antibody targeting drivers of inflammation and fibrosis in chronic GVHD. source